{
    "nct_id": "NCT01002079",
    "title": "A Study of the Effect of Concomitant Administration of Rifampin on the Pharmacokinetics of BMS-708163 in Healthy Subjects",
    "status": "COMPLETED",
    "last_update_time": "2011-01-24",
    "description_brief": "The purpose of the study is to determine if the concomitant administration of rifampin with BMS-708163 will affect the Pharmacokinetics of BMS-708163 and to assess safety and tolerability of co-administration BMS-708163 and rifampin",
    "description_detailed": "N/A",
    "phase": [
        "PHASE1"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "BASIC_SCIENCE",
    "results": null,
    "target_category": "disease-targeted small molecule",
    "drug": [
        "BMS-708163 (avagacestat)"
    ],
    "placebo": [],
    "explanation_target": [
        "Reason: The trial tests BMS-708163, which is a small-molecule gamma-secretase inhibitor developed to reduce amyloid-\u03b2 production (i.e., targeting Alzheimer\u2019s pathology/disease-modifying mechanism). \ue200cite\ue202turn0search0\ue202turn0search4\ue201",
        "Act: Key extracted details \u2014 drug: BMS-708163 (avagacestat); mechanism: selective \u03b3-secretase inhibitor targeting A\u03b2 synthesis; trial described is a drug\u2013drug interaction/PK study of concomitant rifampin with BMS-708163 (NCT01002079). \ue200cite\ue202turn0search4\ue202turn0search6\ue202turn1search5\ue201",
        "Reflect: Classification check \u2014 avagacestat is a small-molecule inhibitor aimed at Alzheimer\u2019s pathological mechanism (amyloid production), so it fits the definition of 'disease-targeted small molecule' rather than a biologic, cognitive enhancer, or symptom-management intervention. No ambiguity in the mechanism from the sources; therefore the assigned category is appropriate. \ue200cite\ue202turn0search0\ue202turn0search3\ue201",
        "Web search results used (selected): PubMed/Clinical Therapeutics descriptions of BMS-708163 (avagacestat) as a \u03b3\u2011secretase inhibitor and its pharmacodynamic effects on A\u03b2. \ue200cite\ue202turn0search0\ue202turn0search3\ue201",
        "Clinical trial registry / listing showing the rifampin drug\u2013drug interaction study (NCT01002079) assessing pharmacokinetics and safety of concomitant rifampin + BMS-708163. \ue200cite\ue202turn0search6\ue202turn1search5\ue201"
    ],
    "agent_type": "A) Amyloid beta",
    "explanation_agent": [
        "Reason: The investigational drug BMS-708163 (avagacestat) is a small\u2011molecule \u03b3\u2011secretase inhibitor developed to reduce production of amyloid\u2011\u03b2 peptides (A\u03b2) by inhibiting APP cleavage, i.e., it directly targets the amyloid production pathway. \ue200cite\ue202turn0search4\ue202turn0search2\ue202turn1search6\ue201",
        "Act: Extracted details \u2014 drug: BMS\u2011708163 (avagacestat); mechanism: selective \u03b3\u2011secretase inhibitor that lowers A\u03b240/A\u03b242 in CSF and plasma; trial type: a pharmacokinetic / drug\u2013drug interaction study assessing concomitant rifampin with BMS\u2011708163 (NCT01002079). These details support classification under the CADRO category for amyloid\u2011beta. \ue200cite\ue202turn1search6\ue202turn1search3\ue202turn0search4\ue201",
        "Reflect: Classification check \u2014 the intervention\u2019s primary biological focus is inhibition of \u03b3\u2011secretase to reduce A\u03b2 production, which maps specifically to CADRO category A) Amyloid beta (not to inflammation, tau, synaptic plasticity, etc.). No evidence in the description that the trial is multi\u2011target or non\u2011therapeutic, so 'A) Amyloid beta' is the appropriate category. \ue200cite\ue202turn0search4\ue202turn0search2\ue201",
        "Web search results used: key sources confirming mechanism and trial registry: (1) Discovery/evaluation of BMS\u2011708163 as a potent, selective \u03b3\u2011secretase inhibitor. \ue200cite\ue202turn0search4\ue201 (2) Product/compound descriptions noting A\u03b2 lowering and \u03b3\u2011secretase activity. \ue200cite\ue202turn0search2\ue202turn0search3\ue201 (3) Clinical/pharmacodynamic reports showing CSF A\u03b2 reductions with avagacestat. \ue200cite\ue202turn1search6\ue202turn1search8\ue201 (4) Clinical trial registry entry for the rifampin drug\u2013drug interaction study (NCT01002079). \ue200cite\ue202turn1search3\ue202turn1search0\ue201"
    ]
}